A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone

Journal of Controlled Release

Volumn 154, Issue 1, 2011, Pages 27-34

  Mero, Anna ^a   Schiavon, Mariano ^a   Veronese, Francesco M ^a   Pasut, Gianfranco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bio catalysis; Drug delivery; PEGylation; Protein modification; Therapeutic proteins

Indexed keywords

ALTERNATIVE METHODS; BIO-CATALYSIS; CHEMICAL PROCEDURES; COSOLVENTS; HUMAN GROWTH HORMONE; IN-VIVO; MICROBIAL TRANSGLUTAMINASE (MTGASE); PEGYLATION; PHARMACOLOGICAL PROPERTIES; PROTEIN MODIFICATION; REACTION MIXTURE; SALMON CALCITONIN; SECONDARY STRUCTURES; SITE-SELECTIVE CONJUGATION; SUBSTRATE PROTEINS; THERAPEUTIC PROTEIN; TRANSGLUTAMINASES;

AMINO ACIDS; CATALYSIS; DRUG DELIVERY; ENZYMES; GLYCOLS; MOTION PICTURE EXPERTS GROUP STANDARDS; POLYETHYLENE GLYCOLS; SUBSTRATES;

PROTEINS;

HUMAN GROWTH HORMONE; MACROGOL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SALCATONIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIUM CONJUGATION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME STABILITY; FEMALE; ISOMER; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RAT; STREPTOMYCES; STREPTOMYCES MOBARAENSIS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CALCITONIN; CALCIUM; CIRCULAR DICHROISM; DRUG CARRIERS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTRATE SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL; TRANSGLUTAMINASES;

EID: 79960925703     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.04.024     Document Type: Article

References (41)

1. J.M. Harris, R.B. Chess, Effect of PEGylation on pharmaceuticals, Nat. Rev. Drug Discov. 2 (2003) 214-221. (Pubitemid 37361666)
2. G. Pasut, F.M. Veronese, Polymer-drug conjugation, recent achievements and general strategies, Prog. Polym. Sci. 32 (2007) 933-961.
3. A. Mero, F.M. Veronese, The impact of PEGylation on biological therapies, BioDrugs 22 (2008) 315-329.
4. F.M. Veronese, G. Pasut, PEGylation, successful approach to drug delivery, Drug Discov. Today 10 (2005) 1451-1458. (Pubitemid 41483874)
5. L.M. Graham, Pegaspergase: a review of clinical studies, Adv. Drug Deliv. Rev. 55 (2003) 1293-1302.
6. Y. Levy, M.S. Hershfield, C. Fernandez-Mejia, Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase, J. Pediatr. 113 (1988) 312-317.
7. M.J. Roberts, M.D. Bentley, J.M. Harris, Chemistry for peptide and protein PEGylation, Adv. Drug Deliv. Rev. 54 (2002) 459-476. (Pubitemid 34615543)
8. C.J. Fee, J.M. Van Alstine, PEG-proteins: reaction engineering and separation issues, Chem. Eng. Sci. 61 (2006) 924-939.
9. Y.S. Wang, S. Youngster, M. Grace, Structural and biological characterization of PEGylated recombinant interferon alpha-2b and its therapeutic implications, Adv. Drug Deliv. Rev. 54 (2002) 547-570. (Pubitemid 34618512)
10. S.P. Monkarsh, Y. Ma, A. Aglione, P. Bailon, D. Ciolek, B. DeBarbieri, M.C. Graves, K. Hollfelder, H. Michel, A. Palleroni, J.E. Porter, E. Russoman, S. Roy, Y.C. Pan, Positional isomers of mono-pegylated interferon a-2a: isolation, characterization, and biological activity, Anal. Biochem. 247 (1997) 434-440. (Pubitemid 27200182)
11. P. Bailon, A. Palleroni, C.A. Schaffer, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis, Bioconjug. Chem. 12 (2001) 195-202. (Pubitemid 32235471)
12. O.B. Kinstler, D.N. Brems, S.L. Lauren, Characterization and stability of N-terminally PEGylated rhG-CSF, Pharm. Res. 13 (1996) 996-1002.
13. S. Balan, J.W. Choi, A.Godwin, I. Teo, C.M. Laborde, S.Heidelberger,M. Zloh, S. Shaunak, S. Brocchini, Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge, Bioconjug. Chem. 18 (2007) 61-76.
14. M. Zloh, S. Shaunak, S. Balan, S. Brocchini, Identification and insertion of 3-carbon bridges in protein disulfide bonds: a computational approach, Nat. Protoc. 2 (2007) 1070-1083.
15. H. Sato, Enzymatic procedure for site-specific PEGylation, Adv. Drug Deliv. Rev. 54 (2002) 487-504.
16. D. Aeschlimann, M. Paulsson, Transglutaminases: protein cross-linking enzymes in tissues and body fluids, Thromb. Haemost. 71 (1994) 402-415.
17. K. Yokoyama, N. Nio, Y. Kikuchi, Properties and applications of microbial transglutaminase, Appl. Microbiol. Biotechnol. 64 (2004) 447-454. (Pubitemid 38686152)
18. A.Mero,B. Spolaore, F.M.Veronese,A. Fontana, Transglutaminase-mediated- PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG, Bioconjug. Chem. 20 (2009) 384-389.
19. A. Fontana, B. Spolaore, A. Mero, F.M. Veronese, Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase, Adv. Drug Deliv. Rev. 60 (2008) 13-28.
20. X. Zhao, A.C. Shaw, J. Wang, C.C. Chang, J. Deng, J. Su, A novel high-throughput screening method for microbial transglutaminases with high specificity toward Gln141 of human growth hormone, J. Biomol. Screen. 15 (2010) 206-212.
21. J. Buchardt, H. Selvig, P.F. Nielsen, J.N. Langeland, Transglutaminase-mediated methods for site-selective modification of human growth hormone, Pep. Sci. 94 (2010) 229-235.
22. M. Sukumar, S.M. Storms, M.R. De Felippis, Non-native intermediate conformational states of human growth hormone in the presence of organic solvents, Pharm. Res. 22 (2005) 789-796.
23. T. Arvinte, A.F. Drake, Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants, J. Biol. Chem. 268 (1993) 6408-6414.
24. B.W. Purdue, N. Tilakaratne, P.M. Sexton, Molecular pharmacology of the calcitonin receptor, Receptors Channels 8 (2002) 243-255.
25. L.A. Denson, Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications, Expert Opin. Drug Metab. Toxicol. 4 (2008) 1569-1580.
26. R. Clark, K. Olson, G. Fuh, M. Marian, D. Mortensen, G. Teshima, S. Chang, H. Chu, V. Mukku, E. Canova-Davis, T. Somers, M. Cronin, M. Winkler, J.A. Wells, Long-acting growth hormones produced by conjugation with polyethylene glycol, J. Biol. Chem. 271 (1996) 21969-21977.
27. G. Pasut, A. Mero, F. Caboi, S. Scaramuzza, L. Sollai, F.M. Veronese, A new PEG-beta-alanine active derivative for releasable protein conjugation, Bioconjug. Chem. 19 (2008) 2427-2431.
28. Y.S. Youn, J.Y. Jung, S.H. Oh, S.D. Yoo, K.C. Lee, Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behaviour and in vivo hypocalcaemic efficacy, J. Control. Release 114 (2006) 334-342. (Pubitemid 44310815)
29. S.M. Ryan, X. Wang, G. Mantovano, C.T. Sayers, D.M. Haddleton, D.J. Brayden, Conjugation of salmon calcitonin to a combed-shaped end functionalized poly (poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate, J. Control. Release 135 (2009) 51-59.
30. N. Grossowicz, E. Wainfan, E. Borek, H. Waelsch, The enzymatic formation of hydroxamic acids from glutamine and asparagines, J. Biol. Chem. 187 (1950) 111-125.
31. L. Cui, G. Du, D. Zhang, X. Fan, J. Chen, Stability and conformational changes of transglutaminase from Streptomyces hygroscopicus in ethanol-aqueous medium, Process Biochem. 43 (2008) 887-891.
32. L.M. Simon, M. Kotorman, A. Szabo, G. Garab, I. Laczko, Effects of polyethylene glycol on stability of a-chymotrypsin in aqueous ethanol solvent, Biochem. Biophys. Res. Commun. 317 (2004) 610-613. (Pubitemid 38452526)
33. M. Pazhang, K. Khajeh, B. Ranjbar, S. Hosseinkhani, Effects of water-miscible solvents and polyhydroxy compounds on the structure and enzymatic activity of thermolysin, J. Biotechnol. 127 (2006) 45-53. (Pubitemid 46107118)
34. R.P. Meadows, E.P. Nikonowicz, C.R. Jones, J.W. Bastian, D.G. Gorenstein, Two-dimensional NMR and structure determination of salmon calcitonin in methanol, Biochemistry 30 (1991) 1247-1254.
35. A. Motta, M.A. Castiglione-Morelli, N. Goud, P.A. Temessi, Sequential proton NMR assignment and secondary structure determination of salmon calcitonin in solution, Biochemistry 28 (1989) 7996-8002. (Pubitemid 19252879)
36. P. Amodeo, A. Motta, G. Strazzullo, M.A. Castiglione-Morelli, Conformational flexibility in calcitonin: the dynamic properties of human and salmon calcitonin in solution, J. Biomol. NMR 13 (1999) 161-174. (Pubitemid 29089226)
37. Y.S. Wang, S. Youngster, J. Bausch, R. Zhang, C. McNemar, D.F. Wyss, Identification of the major positional isomer of pegylated interferon alpha-2b, Biochemistry 39 (2000) 10634-10640.
38. S.D. Stroop, H. Nakamuta, R.E. Kuestner, E.E. Moore, R.M. Epand, Determinants for calcitonin analog interaction with the calcitonin receptor, N-terminus and transmembrane-loop regions, Endocrinology 137 (1999) 4752-4756.
39. K.C. Lee, S.C. Moon, M.O. Park, J.T. Lee, D.H. Na, S.D. Yoo, H.S. Lee, P.P. DeLuca, Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins, Pharm. Res. 16 (1999) 813-818. (Pubitemid 29284190)
40. Y.S. Youn, D.H. Na, K.C. Lee, High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation, J. Control. Release 117 (2007) 371-379. (Pubitemid 46217941)
41. Y.S. Youn, M.-J. Kwon, D.H. Na, S.Y. Chae, S. Lee, K.C. Lee, Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonim: optimization by PEG size selection, J. Control. Release 125 (2008) 68-75. (Pubitemid 350198681)